Mark DePristo is CEO and co-founder of BigHat Biosciences, a Bay Area startup developing safer, more effective antibody therapies for patients using machine learning and synthetic biology. Mark founded and led the Genomics team in Google Brain, was Vice President of Informatics at SynapDx, and co-director of Medical and Population Genetics at the Broad Institute. He has a BA in Computer Science and Math from Northwestern University, a PhD in Biochemistry from the University of Cambridge as a Marshall Scholar, and was a Damon Runyon Fellow at Harvard University in evolutionary biology. Dr. DePristo's academic articles are widely published and have received more than 120,000 citations.